By fusion with PD-1 antibody, this bispecific PD-1-IL-2v demonstrates a robust anti-tumor efficacy at a high-dose level (mAb level) in comparison with the same dose of PD-1 antibody, indicating its potential dual-MOAs (mechanism of actions) as a safe and efficacious “in-cis” IL-2 agonist with PD-1/L1 blocking function. Here, IL2 is linked to neoplasm.